Pioglitazone: Effect on CYP3A4 activity

Journal of Clinical Pharmacology

Volumn 42, Issue 12, 2002, Pages 1299-1302

  Nowak, Sandra N ^a   Edwards, David J ^a   Clarke, Anthony ^b   Anderson, Gail D ^c   Jaber, Linda A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; BIOCHEMICAL MARKER; CYTOCHROME P450 3A4; HYDROCORTISONE; PIOGLITAZONE;

ADULT; ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; URINARY EXCRETION;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; MALE; PROSPECTIVE STUDIES; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036891156     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002042012009     Document Type: Article

References (20)

1. Henry RR: Thiazolindinediones. Endocrinol Metab Clin North Am 1997;26:553-573.
2. Koup JR, Anderson GD, Loi CM: Effect of troglitazone on urinary excretion of 6β-hydroxycortisol. J Clin Pharmacol 1998;38:815-818.
3. Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ: Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. J Clin Pharmacol 1999;39:410-417.
4. Loi CM, Stern R, Vassos AB, Koup JR, Sedman AJ: Effect of troglitazone on terfenadine pharmacokinetics [abstract]. Clin Pharmacol Ther 1998;63:228.
5. Loi CM, Stern R, Abel R, Koup JR, Vassos AB, Sedman AJ: Effect of troglitazone on PK and PD of atrovastatin [abstract]. Clin Pharmacol Ther 1999;65:186.
6. ACTOS [U.S. package circular], July 1999.
7. Yamazaki H, Suzuk M, Tane K, Shimada N, Nakajima M, Yokoi T: In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone. Xenobiotica 2000;30:61-70.
8. Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, et al: Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2000;41:573-581.
9. Morita H, Oki Y, Ito T, Ohishi H, Suzuki S, Nakamura H: Administration of troglitazone, but not pioglitazone reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care 2001;24:788-789.
10. Carey RA, Liu Y: Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy pharmacokinetics [abstract]. Diabetes Care 2000;49(suppl. 1):405-P.
11. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Burstein AH, Reiss WG, Kantor E, Anderson GD: Cytochrome P450 3A4 activity in premenopausal and postmenopausal women based on 6-β-hydroxycortisol/cortisol ratios. Pharmacotherapy 1998;18:1271-1276.
13. Roots I, Holbe R, Hovernann W, et al: Quantitative determination by HPLC of urinary 6β-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 1979;16:63-71.
14. Breidenbach Th, Hoffman MW, Becker Th, Schlitt H, Klempnauer J: Drug interaction of St. Johns wort with ciclosporin. Lancet 2000;355:1912.
15. Ernest E: Second thoughts about safety of St. John's wort. Lancet 1999;354:2014-2016.
16. Roby CA, Anderson GD, Kantor E, Dryer DA, Burnstein AH: St. John's wort: Effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451-457.
17. Bienvenu T, Rey E, Pons G, D'Athis P, Olive G: A simple non-invasive procedure for the investigation of cytochrome P-450 III A dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 1991;29:441-445.
18. Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, Azuma J: Circadian variation of the urinary 6-β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP 3A activity. Eur J Clin Pharmacol 2000;55:861-865.
19. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, et al: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62:162-172.
20. Yasui-Furukori N, Kondo T, Kubota T, Otake H, Ohkubo T, Nagasaki T, Sugawara K, Chiba K, Otani K, Kaneko S: No correlation between the urinary ratio of 6β-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. Eur J Clin Pharmacol 2001;57:285-288.